 | Up a level |
Meggiolaro, Angela; Blankart, Carl Rudolf; Stargardt, Tom; Schreyögg, Jonas (2023). An econometric approach to aggregating multiple cardiovascular outcomes in German hospitals. European journal of health economics, 24(5), pp. 785-802. Springer 10.1007/s10198-022-01509-y
Blankart, Carl Rudolf; Stargardt, Tom (2017). Preferred supplier contracts in post-patent prescription drug markets. Health Care Management Science, 20(3), pp. 419-432. Springer 10.1007/s10729-016-9362-6
Frey, Simon; Blankart, Carl Rudolf; Stargardt, Tom (2016). Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. PharmacoEconomics, 34(5), pp. 479-498. Adis International / Springer 10.1007/s40273-015-0367-7
Achelrod, Dmitrij; Blankart, Carl Rudolf Berchtold; Linder, Roland; von Kodolitsch, Yskert; Stargardt, Tom (2014). The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. Orphanet journal of rare diseases, 9(1), p. 90. BioMed Central 10.1186/1750-1172-9-90
Blankart, Carl Rudolf Berchtold; Koch, Taika; Linder, Roland; Verheyen, Frank; Schreyögg, Jonas; Stargardt, Tom (2013). Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet journal of rare diseases, 8(1), p. 32. BioMed Central 10.1186/1750-1172-8-32
Blankart, Carl Rudolf; Stargardt, Tom; Schreyögg, Jonas (2011). Availability of and Access to Orphan Drugs : An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia. PharmacoEconomics, 29(1), pp. 63-82. Adis International 10.2165/11539190-000000000-00000
